Recently, the CDIE 2026 Digital Innovation Expo was held in Shanghai. As the first index standard in China to evaluate the digitalization level of enterprises, the CDI Huaying Digitalization Index Award was unveiled at this conference. Xbiome, with its strong AI-driven research and product development capabilities in human gut microbiota, as well as high-quality probiotics and FMT products combining "AI + BT," was honored with the award.Top 10 AI Fusion Innovation Enterprises, andAI Innovation Leader in the Healthcare IndustryAward; Co-founder and CEO Dr. Tan Yan ratedPioneer in AI Technology ImplementationAward.
This conference"Transforming AI into Productivity"Themed as, the selection of the series of awards is based on a multi-index, multi-dimensional fair, just, and open system to uncover China's digital innovation benchmarks across all industries. It aims to establish industry exemplars, unlock leading industry transformation methodologies, and inject core momentum into sustainable high-quality development, attracting hundreds of top companies from various industries, such as Angel, SAIC Maxus, Great Wall Motors, Wong Lo Kat, and IM Motors, to participate enthusiastically in the evaluation.Xbiome, as a leading enterprise in China in the research, technology, and product development of gut microbiome, won three major awards at its first participation in the selection.
The relationship between gut microbiota and disease health has become a scientific hotspot in recent years; translating cutting-edge research into pharmaceutical and healthcare products represents one of the most sought-after innovation trends in the current life sciences field. Xbiome, a leading AI-driven enterprise in China specializing in microbiome therapeutics and healthcare product development, has established an AI-focused microbiome research and product development platform. Centered on gut microbiota sourced from the Chinese population, Xbiome has integrated the entire process of "AI + BT," "large-scale computational analysis of life science data + strain screening + mechanism research + functional validation + clinical trials and industrialization."
In recent years, Xbiome has rapidly transformed cutting-edge scientific technologies into research publications, invention patents, and accessible microbiome products for all. In pharmaceuticals, Xbiome has developed over a dozen innovative pipelines, with four projects entering clinical stages, two in Phase II clinical trials, leading the industry in drug development progress and repeatedly establishing milestones in Asia's microbiome pharmaceutical field. Relying on its leading strain screening platform, Xbiome conducts research on functional strains of human-derived probiotics in the Chinese population, independently developing star strains such as XA-1416, XA-2103, XA-1267, XA-768, XA-02D, and XA-8187. It carries out detailed mechanism studies, functional validations, and patent protections, converting strain assets into probiotic products. In the FMT (fecal microbiota transplantation) sector, Xbiome, supported by a production system regulated and recognized by the U.S. FDA, develops an FMT product matrix, offering new solutions for consumers' lifelong health.
By the end of March 2026, Xbiome launched three new FMT products — Standard Edition, Precision Edition, and Super Edition — becoming a focal point in the industry.The Standard Edition of FMT repairs the intestinal barrier from the source and improves overall health; the Precision Edition of FMT precisely addresses health needs through AI-based precise matching + quasi-pharmaceutical-grade active microbial communities; the Super Edition of FMT provides users with customized intestinal microbiota transplantation + long-term one-on-one health management by functional medicine experts, fulfilling users' health aspirations in gut rejuvenation, body reshaping, and anti-aging through gut-related interventions.Xbiome Builds a Leading Health Donor Bank with a Thousand-to-One Selection; Develops Disease Classification and Risk Prediction Models Based on Large Language Models, and Precise AI Matching Algorithms, Empowering FMT Products to Be Safer, More Scientific, Higher Standard, and More Personalized with AI.
With advanced technology platforms and scientific research capabilities, Xbiome's FMT products have been applied in the national science and technology major projects for four major chronic diseases. Its star strains have been praised by national-level media such as Xinhua News Agency and "Outlook East" as typical cases of "China's bacteria."The recognition with three major industry-wide awards this time is a comprehensive acknowledgment of Xbiome's AI-empowered scientific research, product development, and personalized service capabilities.Xbiome will continue to build technology platforms and products around AI+Science and AI+Service, providing microbiome examples for constructing a Healthy China and safeguarding human health.
-End-